Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes  by Desaphy, Jean-François et al.
Experimental Neurology 248 (2013) 530–540
Contents lists available at ScienceDirect
Experimental Neurology
j ourna l homepage: www.e lsev ie r .com/ locate /yexnrFunctional characterization of ClC-1 mutations from patients
affected by recessive myotonia congenita presenting with
different clinical phenotypesJean-François Desaphy a,⁎, Gianluca Gramegna a, Concetta Altamura a,
Maria Maddalena Dinardo a, Paola Imbrici a, Alfred L. George Jr. b,
Anna Modoni c, Mauro LoMonaco c, Diana Conte Camerino a
a Section of Pharmacology, Department of Pharmacy & Drug Sciences, University of Bari-Aldo Moro, Bari, Italy
b Division of Genetic Medicine, Vanderbilt University, Nashville, TN, USA
c Department of Neurosciences, Catholic University, Rome, Italy⁎ Corresponding author at: Sezione di Farmacologia, Di
del Farmaco, via Orabona 4 — campus, 70125 Bari, Italy.
E-mail address: jfdesaphy@farmbiol.uniba.it (J.-F. Desa
0014-4886 © 2013 The Authors. Published by Elsevier Inc
http://dx.doi.org/10.1016/j.expneurol.2013.07.018a b s t r a c ta r t i c l e i n f oArticle history:
Received 11 June 2013
Revised 18 July 2013
Accepted 25 July 2013
Available online 8 August 2013
Keywords:
Acetazolamide
Chloride channel mutation
ClC-1 chloride channel
Genotype–phenotype relationship
Myotonia congenita
Non-dystrophic myotonia
Patch-clamp
Transitory weaknessMyotonia congenita (MC) is caused by loss-of-function mutations of the muscle ClC-1 chloride channel. Clinical
manifestations include the variable association of myotonia and transitory weakness. We recently described a
cohort of recessive MC patients showing, at a low rate repetitive nerves stimulation protocol, different values
of compound muscle action potential (CMAP) transitory depression, which is considered the neurophysiologic
counterpart of transitory weakness. From among this cohort, we studied the chloride currents generated by
G190S (associated with pronounced transitory depression), F167L (little or no transitory depression), and
A531V (variable transitory depression) hClC-1 mutants in transfected HEK293 cells using patch-clamp. While
F167L had no effect on chloride currents, G190S dramatically shifts the voltage dependence of channel activation
and A531V reduces channel expression. Such variability in molecular mechanisms observed in the hClC-1
mutants may help to explain the different clinical and neurophysiologic manifestations of each ClCN1mutation.
In addition we examined ﬁve different mutations found in compound heterozygosis with F167L, including the
novel P558S, and we identiﬁed additional molecular defects. Finally, the G190S mutation appeared to impair
acetazolamide effects on chloride currents in vitro.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Recessive (Becker's disease) and dominant (Thomsen's disease)
myotonia congenita are caused bymutations in the CLCN1 gene encoding
the voltage-dependent chloride ClC-1 channel quite exclusively
expressed in the sarcolemma (George et al., 1993; Koch et al., 1992).
Mutations impair ion channel function and/or expression, and are
predicted to reduce sarcolemmal chloride conductance that normally
stabilizes muscle ﬁber membrane potential. A chloride conductance
reduced by more than 50% predisposes to membrane hyper-excitability
characterized by spontaneous action potential runs or abnormal after-
discharges that impede muscle relaxation upon cessation of nerve input.
Functional ClC-1 channels are composed of two identical subunits, each
forming an independent chloride ion-conducting pore (Saviane et al.,partimento di Farmacia-Scienze
phy).
. Open access under CC BY-NC-ND lice1999). A dominant ClC-1 mutant is thus expected to exert a dominant-
negative effect on the associated wild-type (WT) subunit in order to
reduce the chloride conductance enough to evoke clinical myotonia.
On the other hand, a recessive mutation likely affects only the encoded
subunit, and both alleles must be mutated to cause the disease.
Myotonia congenita is clinically characterized by two contrasting
phenomena: the abnormal membrane excitation leading to myotonia
and the muscle inexcitability manifesting as transitory weakness (Trip
et al., 2009). Interestingly, a signiﬁcant clinical variability is usually
observed in patients affected by either dominant or recessive forms of
the disease and only a few studies have addressed the detailed
genotype/phenotype relationship (Colding-Jorgensen, 2005). The
functional characterization of ClC-1 channel mutations is however
of great clinical relevance, because this should help to reveal the under-
lying mechanisms of each speciﬁc symptom and to deﬁne strategies to
better address treatment in individual myotonic patients. For instance,
we recently showed that patients suffering from sodium channel
myotonia may obtain huge therapeutic improvements from such a
pharmacogenetics strategy (Desaphy et al., 2004, 2013). Indeed,
although the usefulness of mexiletine in sodium and chloride channel
myotonias has been recently conﬁrmed by a clinical trial (Statlandnse.
531J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540et al., 2012), we have demonstrated that some sodium channel
mutations are less responsive to mexiletine in vitro, and that patients
carrying those mutations may greatly beneﬁt from another drug, such
as ﬂecainide.
In a recent study, we described a cohort of patients affected by
autosomal recessive MC (Modoni et al., 2011). We performed a low-
rate repetitive nerve stimulation protocol to detect transitory depression
of the compound action potential, which represents the neurophysiolog-
ic counterpart of transitoryweakness (Aminoff et al., 1977).We observed
that patients heterozygous for the G190S mutation presented with pro-
nounced transitory depression and transitory weakness, whereas these
features were very limited in patients carrying the F167L mutation. By
contrast, patients heterozygous for the A531V mutation showed a re-
markable variation in transitory depression. On the basis of these obser-
vations, the present study was undertaken to characterize the
biophysical behavior of G190S, F167L, and A531V channel mutants
expressed in HEK293 cells using the patch-clamp technique. Because
chloride currents generated by F167L appeared quite similar to wild-
type ones, we also studied the effects of ﬁve different mutations found
in patients with compound heterozygosity for F167L and R105C,
G284R, G355R, Y686X, or a newly discovered mutation (P558S). The
experiments were performed using an intracellular solution containing
low amount of chloride (4 mM), which is close to the physiological
concentration in muscle ﬁbers, or larger amount of chloride (134 mM),
which allows to record huge chloride currents and to easily analyze
deactivation kinetics. In addition, we report the effects of acetazolamide
on wild-type and G190S chloride currents, because the drug has been
shown to negatively shift the voltage-dependence of channel activation
(Eguchi et al., 2006).
Material and methods
Site-directedmutagenesis and expression ofWT andmutant hClC-1 channels
Mutations were introduced into the plasmid pRcCMV-hClC-1
containing the full-length wild-type (WT) hClC-1 cDNA using the
QuickChange™ site-directed mutagenesis kit (Stratagene Cloning
Systems). The complete coding region of the cDNA was sequenced
to exclude polymerase errors. At least two independent mutant
clones were tested for electrophysiological studies. Human embry-
onic kidney 293 (HEK293) cells were transiently transfected with a
mixture of the hClC-1 (10 μg) and CD8 reporter plasmids (1 μg)
using the calcium–phosphate precipitation method (Desaphy
et al., 2001). Cells were examined between 36 and 80 h after trans-
fection. Only cells decorated with anti-CD8 antibody-coated
microbeads (Dynabeads M450, Invitrogen) were used for patch-
clamp recordings.
Electrophysiology
Standard whole-cell patch-clamp recordings were performed at
room temperature (~20 °C) using an Axopatch 200B ampliﬁer (Axon
Instruments). The composition of the extracellular solution was (in
mM): 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2 and 5 HEPES, and the pH was
adjusted to 7.4withNaOH. The high-chloride pipette solution contained
(in mM): 130 CsCl, 2 MgCl2, 5 EGTA and 10 HEPES, and the pH was
adjusted to 7.4 with CsOH. In this condition, the equilibrium potential
for chloride ions was about −2.8 mV and cells were clamped at the
holding potential (hp) of 0 mV. In the low-chloride internal solution,
cesium chloride was substituted by cesium glutamate.With this pipette
solution, the equilibrium potential for chloride ions was about –92 mV
and cells were clamped at the hp of –95 mV. Pipettes were pulled
from borosilicate glass and had ~3 MΩ resistance, when ﬁlled with
the above pipette solutions. For pharmacological experiments, acetazol-
amide (ACTZ, Sigma-Aldrich) was ﬁrst dissolved in dimethylsulfoxide
(DMSO) then in the external patch solution at the desired ﬁnalconcentration. The ﬁnal DMSO concentration did not exceed 0.2%
(vol/vol) and had no effect on HEK293 cell currents. The patched cell
was continuously exposed to a stream of control or drug-supplemented
bath solution ﬂowing out from a plastic capillary.
Currents were low-pass ﬁltered at 2 kHz and digitized with
sampling rates of 50 kHz using the Digidata 1440A AD/DA converter
(Axon Instr.). Patches with a series resistance voltage error greater
than 5 mV and those with non-negligible leak current were discarded.
Chloride currents were recorded ~5 min after achieving the whole cell
conﬁguration, to allow the pipette solution to equilibratewith the intra-
cellular solution. Voltage-dependent channel activity was measured by
applying speciﬁc voltage step pulses from the hp depending on the
internal chloride concentration, as described in the Results section and
shown in the ﬁgures. Voltage steps were applied every 3 s to allow
complete recovery of current amplitude at the hp between two pulses.
Data were analyzed off-line by using pClamp 10.3 (Axon Instruments)
and SigmaPlot 8.02 (Systat Software GmbH) software. All data are
presented as the mean ± SEM from N patches. The instantaneous and
isochronal current–voltage relationships were drawn by measuring
instantaneous and steady-state currents at the beginning (~1 ms) and
end (~390 ms) of each voltage step. The voltage-dependence of channel
activationwas examined by plotting the apparent open probability (Po)
as a function of membrane potential at the end of the test pulse. The Po
was calculated from normalized instantaneous current amplitude
measured at the start of the tail pulse at −105 mV. The relationship
was ﬁtted with a Boltzmann function,
Po Vð Þ ¼ Minþ 1−Minð Þ= 1þ exp V−V0:5ð Þ=S½ f g ð1Þ
where Min is the minimal value of Po, V0.5 is the half-maximal activation
potential, and S is the slope factor. A double Boltzmann function was
necessary to ﬁt the activation curve of P558S mutant,
Po Vð Þ ¼ Minþ A1= 1þ exp V–V1ð Þ=S1½ f g
þ A2= 1þ exp V–V2ð Þ=S2½ f g: ð2Þ
The time course of current deactivation was examined by ﬁtting
the decay of currents elicited in symmetrical chloride condition
between −200 and −60 mV in 10-mV intervals with a sum of
two exponentials and a time-independent component,
I tð Þ ¼ Afast  exp t=τfastð Þ þ Aslow  exp t=τslowð Þ þ C ð3Þ
where τfast and τslow are the time constants of the fast and slow compo-
nents of current relaxation, and Afast, Aslow, and C are the relative
amplitudes of the fast, slow, and steady-state components of the current.
Results are reported as mean ± SEM from N cells, and statistical
analysis was performed using Student's t-test, with P b 0.05 considered
as signiﬁcant.
Results
Clinical phenotype of myotonia congenita patients
The clinical phenotype of patients carrying all themutations studied
here except P558S was described previously (Modoni et al., 2011).
Brieﬂy, three unrelated patients were found to carry the G190S
mutation in combination with 3 different mutations on the opposite
allele. All three patients showed a pronounced transitory depression
(N50%) upon neurophysiological examination using a 3-Hz repetitive
nerve stimulation protocol. Three individuals from two families carrying
the A531V mutation with compound heterozygosity for two different
nonsense mutations displayed a remarkable variability of transitory
depression upon successive examinations. Finally, eleven patients
from 8 families had the F167L mutation in combination with 7 other
mutations on the opposite allele. All these patients showed a limited
transitory depression ranging from 0 to 23%. The seven compound
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Fig. 1. Voltage-dependence of wild-type and F167L, A531V, and G190S myotonic hClC-1 channels in high intracellular chloride. A) Chloride currents were recorded in HEK293 cells
transfected with wild-type, F167L, or A531V hClC-1 variants. Cells were held at 0 mV and 400 ms voltage pulses were applied from −200 to +120 mV in 10-mV intervals every 3 s.
For clarity only current traces obtained every 20 mV are shown. Chloride currents displayed similar kinetics, but A531V had reduced amplitude. B) Voltage pulses were applied from
−120 to +200 mV to elicit chloride currents in HEK293 cells expressing G190S hClC-1 variant. C) The instantaneous currents were measured at the beginning of test voltage pulses,
normalized with respect to cell capacitance (pA/pF), and reported as a function of voltage. Each point is the mean ± SEM from 10 to 36 cells. The relationships show strong inward
rectiﬁcation for WT, F167L, and A531V channels, although current density was greatly reduced for A531V. The relationship for G190S channels was linear. D) Steady-state currents
were measured at the end of test voltage pulses and reported as mean current density ± SEM in function of voltage. The WT and F167L relationships were very similar, while A531V
generated reduced current densities. The G190S relationship shows a strong outward rectiﬁcation. E) The voltage dependence of activation was determined by plotting the apparent
open probability (Po), calculated from tail currents measured at−105 mV, as a function of test voltage pulses. The relationships obtained from averaged data were ﬁt with a Boltzmann
equation, and ﬁt parameters are reported in Table 1. The activation curves forWT, F167L, and A531Vwere superimposable, whereas G190S channels displayed a positively-shifted voltage
dependence.
532 J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540mutations associated with F167L include 2 intronic, 4 exonic, and 1
unknownmutation. In the present study, we performed the biophysical
characterization of G190S, A531V, and F167Lmutants togetherwith the4 exonic mutants associated with F167L (R105C, G284R, G355R,
Y686X). We also included the biophysical examination of the new
P558S mutation found in combination with F167L in an additional MC
Table 1
Boltzmann parameters of activation relationships of different ClC-1 variants using various
internal chloride concentrations.
Variant [Cl−]i
(mM)
N V0.5
(mV)
S Min
WT 134 15 −69.2 ± 2.3 25.0 ± 1.2 0.04 ± 0.01
44 10 −56.7 ± 2.1 27.5 ± 2.2 0.02 ± 0.01
24 8 −47.1 ± 4.2 30.9 ± 2.3 0.01 ± 0.01
4 8 −30.0 ± 5.0 34.6 ± 3.3 0.02 ± 0.01
F167L 134 36 −70.3 ± 2.4 24.8 ± 0.6 0.08 ± 0.01*
44 5 −57.6 ± 6.1 24.9 ± 1.6 0.02 ± 0.01
24 8 −45.5 ± 3.0 30.8 ± 2.1 0.01 ± 0.01
4 7 −26.2 ± 4.0 27.1 ± 1.4 b0.01
A531V 134 10 −59.6 ± 2.8* 29.4 ± 2.0 0.09 ± 0.02
4 9 −16.4 ± 3.1* 60.0 ± 3.2* 0.08 ± 0.02*
G190S 134 15 +114.5 ± 4.5* 32.9 ± 1.3* 0.04 ± 0.01
4 9 +111.9 ± 11.6* 42.0 ± 2.0 0.02 ± 0.01
R105C 134 6 −73.9 ± 6.4 21.1 ± 1.4 0.11 ± 0.03*
4 6 −39.8 ± 7.1 35.3 ± 2.2 b0.01
P558S 134 8 V1 = −62.9 ± 2.2
V2 = +100.5 ± 4.2
S1 = 17.0 ± 0.8
S2 = 32.9 ± 3.3
0.28 ± 0.02*
4 24 n.d. n.d. n.d.
The internal chloride concentration was modiﬁed by substituting glutamate for chloride
ions. The external chloride concentration was maintained constant at 150 mM. The
activation relationships obtained in each cell were ﬁt with a Boltzmann equation
(Eq. (1)) or a double Boltzmann equation for P558S (Eq. (2)), and ﬁt parameters are
reported as the mean ± SEM from N cells. V0.5 is the half-maximum activation voltage,
S is the slope factor, and Min is the minimal open probability. n.d. not
determined.* indicates signiﬁcant difference (at least P b 0.05) versus WT at the
same internal chloride concentration, as calculated with unpaired Student's t test.
Statistical analysis was not performed for V0.5 and S values of P558S mutant. The
mean relationships obtained from N cells are shown in Figs. 1D, 2D, and 6C.
533J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540patient. This new mutation was found in a sporadic case coming from
Southern Italy. The patient showed a very severe phenotype, with
generalized muscle hypertrophy, in particular of lower limbs, muscle
stiffness, severe myotonia and transitory weakness.
Characterization of mutations associated with various levels of CMAP
transient depression
Chloride currents were elicited in HEK293 cells transfected with the
same amount of either wild-type, F167L, G190S, or A531V hClC-1
chloride channels, using a voltage protocol allowing the determination
of I–V relationships as well as the voltage dependence of activation
(apparent open probability). Results obtained using high intracellular
chloride concentration (134 mM) are shown in Fig. 1. Regarding WT,
F167L, and A531V mutants, cells were held at 0 mV, and voltage steps
were applied between –200 mV and +120 mV in 10 mV intervals,
each followed by a voltage step at –105 mV (Fig. 1A). Preliminary
observations concerning G190S showing low chloride current
amplitude and lack of plateau led us to explore a different voltage
range; thus depolarizing steps were applied between –120 mV and
+200 mV (Fig. 1B). Time between two depolarizing steps was long
enough to maintain a constant current at the holding potential. For
WT, F167L, and A531V channels, instantaneous currents were observed
at each voltage steps, which decreased over time at negative voltages
between –200 and about –60 mV (corresponding to channel deactiva-
tion) or remained stable over time between –50 and+120 mV. Current
amplitudes saturated at voltages greater than +50 mV. In contrast,
G190S channels produced very little currents at negative voltages, and
slowly activating currents at positive voltages. These currents did not
saturate at voltages up to +200 mV.
Instantaneous and steady-state current densities (pA/pF) were
calculated in at least n = 10 cells for each channel variant to draw
mean instantaneous and isochronal I–V relationships (Figs. 1C, D). For
instantaneous currents, the inwardly-rectifying relationships were
nearly superimposable for WT and F167L channels, whereas current
densities were greatly reduced at each voltage for A531V and G190S
channels. Again, for steady-state currents, the I–V curves for WT and
F167L channels were superimposable, and currents ﬂowing through
A531V were greatly lower. In contrast, the I–V relationships of G190S
channels showed a strong outward rectiﬁcation; compared to WT,
G190S current densities were greatly reduced at membrane voltages
within the physiological range and increased only at very positive
voltages.
Voltage dependence of channel activation was determined by
plotting the apparent open probability (normalized instantaneous
currents at −105 mV) versus the voltage of preceding pulses
(Fig. 1E). The relationships for WT, F167L, and A531V channel variants
were well ﬁt with a Boltzmann equation (Eq. (1)) and calculated
parameters are given in Table 1. No signiﬁcant differences were found
between the three channel types. For G190S, no current saturation
was observed and the maximum current for normalization was
arbitrarily taken at +200 mV to draw the relationship. The voltage
dependence of G190S channels appeared signiﬁcantly shifted toward
positive potentials.
With a low intracellular chloride concentration (4 mM), chloride
currents were elicited from the conditioning voltage at –95 mV by a
series voltage steps between −150 and +150 mV (−145 and
+215 mV for G190S) applied every 3 s in 10-mV intervals, followed
by a step to −105 mV (Fig. 2). In these conditions, chloride current
kinetics were similar between the four channel variants, with instanta-
neous currents that remained quite stable over time at the more
negative voltages or followed by slowly activating currents at less
negative or positive voltages. Again, current amplitude plateau was
observed at the more positive voltages except for G190S. Moreover
current densities for A531V andG190Smutants were smaller compared
to WT and F167L channels in the entire voltage range (Figs. 2C, D). Thevoltage dependence of activationwas similar forWT and F167L (Fig. 2E,
Table 1). For A531V, the relationship was steeper and the half-
maximum activation voltage was slightly but signiﬁcantly shifted. For
G190S, the relationship was greatly shifted toward positive potentials.
The lower current densities observed for A531V and G190S within
the physiological range of membrane potentials likely account for the
manifestation of clinical myotonia. In contrast, F167L mutant appeared
very similar to WT, and we thus performed further analysis of this mu-
tant.We repeated the same protocols using pipette solutions containing
intermediate chloride concentrations, 24 and 44 mM, and found no
difference between WT and F167L in current densities (not shown) or
in voltage dependence of activation (Table 1). We also analyzed the
kinetics of current deactivation as a function of voltage in high-
chloride condition. Deactivating currents were ﬁtted with a double
exponential function including a residual current (Eq. (3)). No
difference was found betweenWT and F167L in the two time constants
and in the relative amplitude of the fast, slow, and non-deactivating
components (Fig. 3).
Characterization ofmutations associatedwith F167L in heterozygous carriers
Wecharacterized the function of ClC-1mutants associatedwith F167L
mutation in heterozygous patients, carrying R105C, G284R, G355R,
Y686X (Modoni et al., 2011), and the newly identiﬁed P558S mutation,
on the second allele.
In cells transfected with G284R, G355R, or Y686X, linear currents
of low amplitude most likely corresponding to leak currents were
recorded independent of the internal chloride ion concentration (Fig. 4).
Using high or low chloride intracellular concentration, chloride
currents ﬂowing through R105C were very similar to WT currents
(Fig. 5). Only current density at steady-state was slightly smaller for
R105C compared toWT (Figs. 6A, B). The voltage dependences of activa-
tion of WT and R105C were superimposable (Fig. 6C). Deactivation
kinetics of R105C currents were also very similar to those of WT
channels (Fig. 3).
The cells transfected with P558S showed a singular alteration of chlo-
ride current gating. Using high intracellular chloride conditions, chloride
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Fig. 2. Voltage-dependence of wild-type and F167L, A531V, and G190S myotonic hClC-1 channels in low intracellular chloride. A) Chloride currents were recorded in HEK293 cells
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534 J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540currents displayed a rapid deactivation followed by a slow activation at
negative voltages (Fig. 5). At potentials positive to−100 mV, the kinetics
of P558S currents were very similar to that of WT, but current densities
were greatly reduced (Figs. 6A, B). In high-chloride condition, the appar-
ent Po of P558S was best ﬁt with a double Boltzmann function (Eq. (2))
and showed a signiﬁcant residual Po at negative voltages with about30% of channels remaining open between −200 and –100 mV (Fig. 6C,
Table 1). In low chloride conditions, very small P558S currents were
recorded, which did not saturate at positive voltages. Thus the activation
curve was drawn by arbitrarily normalizing to currents measured at
+150 mV. Because of lack of saturating currents, the ﬁt of activation
curve of P558S with a Boltzmann equation was not satisfactory;
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535J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540the estimated half-maximum activation voltage was approximately
+25 mV. Analysis of deactivation kinetics indicates that the fast and
slow time constants are similar to those found in WT (Fig. 3). However,
compared to WT, the deactivation was incomplete at potentials
more negative to −100 mV, with a greater steady state current.
Effects of acetazolamide on WT and G190S hClC-1 channels
Acetazolamide (ACTZ) is an inhibitor of carbonic anhydrase empiri-
cally used to treat myotonia (Griggs et al., 1978). Recently, it has been
reported that the drug may be able to shift the voltage dependence ofwild-type hClC-1 channel activation toward more negative potentials,
which might contribute to its antimyotonic effects (Eguchi et al.,
2006). Because the G190S mutant induced a large positive shift of acti-
vation voltage dependence, we tested whether ACTZ is able to contrast
G190S defect. The drug was tested at 10, 30, 100 and 300 μM on wild-
type and G190S chloride currents in HEK293 cells (Fig. 7). The main
effect of 100 μM ACTZ on WT channels consists in an ~50% increase of
steady state currents at negative voltages (see arrows in Figs. 7A–C).
The same effect was observed with 300 μM ACTZ on WT channels (not
shown). In contrast, 300 μM ACTZ had little effect on G190S chloride
currents, with variation in steady-state current amplitude minor than
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Fig. 4. Representative current traces elicited in HEK293 cells transfected with G284R, G355R, and Y686X myotonic hClC-1 mutants, using high and low intracellular chloride.
536 J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–54010% (Fig. 7D). The voltage-dependence of WT channel activation was
negatively shifted by ~15 mVbyACTZ, whereas the voltage dependence
of G190S remained quite unaffected by the drug (Figs. 7E, F). These
experiments were performed using an internal solution containing100 ms
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Fig. 5. Representative current traces elicited in HEK293 cells transfected with R105C10 mM HEPES. Because it was proposed that ACTZ exerts its effects on
ClC-1 through intracellular acidiﬁcation, we also tested 100 μM ACTZ
on WT and G190S chloride currents using only 1 mM HEPES in the pi-
pette solution. In these conditions, the shift of channel activation voltageLow Cl -Inside
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537J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540dependencewas−20.6 ± 7.6 mV (n = 4) forWT and−3.3 ± 1.9 mV
(n = 4) for G190S. This conﬁrms the insensitivity of G190S to ACTZ.
Discussion
Although an overall reduction of sarcolemmal chloride currents is
clearly responsible for the development of myotonia, little is known
about the relation between the molecular alteration in ClC-1 channel
function induced by each mutation and speciﬁc clinical features. Inthis study,we functionally characterize a large number of ClC-1mutations
in an attempt to complete our understanding of the genotype/phenotype
relationship.
The G190S mutation induces a dramatic positive shift of activation
voltage-dependence resulting in merely no detectable chloride currents
within the physiological range. This conﬁrms the results of a recently
published study (Ulzi et al., 2012), but this shift was greatly accentuated
in our hands. Thismay result in part fromdifferences in data analysis, be-
causewe used currentsmeasured at different voltages for normalization.
CBA
D
FE
Membrane Potential (mV)
N
or
m
al
iz
ed
 C
hl
or
id
e 
Cu
rr
en
ts
  
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
CTRL Instantaneous 
CTRL Steady State 
ACTZ Instantaneous
ACTZ Steady State
100 µM ACTZ on WT
Membrane Potential (mV)
N
or
m
al
iz
ed
 C
hl
or
id
e 
Cu
rr
en
ts
  
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
CTRL Instantaneous 
CTRL Steady State 
ACTZ Instantaneous
ACTZ Steady State
300 µM ACTZ on G190S
V0.5 shift (mV)
A
CT
Z 
(μM
)
10
30
100
300
WT 
G190S 
Membrane Potential (mV)
-200 -150 -100 -50 0 50 100 150 -150 -100 -50 0 50 100 150 200
-25 -20 -15 -10 -5 0-200 -150 -100 -50 0 50 100 150 200
A
pp
ar
en
t P
o
0.0
0.2
0.4
0.6
0.8
1.0
1.2 WT-CTRL 
WT-ACTZ 100 μM
G190S-CTRL 
G190S-ACTZ 300 μM 
100 ms
5 nA
CTRL
100 ms
5 nA
100 µM ACTZ
Fig. 7. Effects of acetazolamide (ACTZ) onwild-type (WT) andG190S hClC-1 chloride currents. Representative chloride currents are shown before (A) and after (B) application of 100 μMACTZ
to an HEK293 cell expressing WT hClC-1 channel. The internal chloride ion concentration was 134 mM. Cells were held at 0 mV and 400 ms voltage pulses were applied from −200 to
+120 mV in 10-mV intervals every 3 s. For clarity only current traces obtained every 20 mV are shown. C) The current–voltage relationships were drawn for instantaneous and steady-
state WT chloride currents, elicited before and after ACTZ application, and normalized with respect to instantaneous current recorded at −200 mV. Each point is the mean ± SEM from 7
cells. D) The chloride currents carried byG190S hClC-1mutantweremeasured before and after application of 300 μMACTZ to draw instantaneous and isochronal current–voltage relationships.
Each point is themean ± SEM from6 cells. E) The voltage dependence of activation ofWT (n = 7) andG190S (n = 6) channelswas examined before and after application of 100 and 300 μM
ACTZ, respectively. F) Thehalf-maximumactivation potential (V0.5) ofWTandG190S channelswas determinedbefore and after application of variousACTZ concentrations, byﬁtting the voltage
dependence of activation with a Boltzmann function (Eq. (1)). The bar graph reports the shift of V0.5 induced by ACTZ. Each bar is the mean ± SEM from 3-to-7 cells.
538 J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540Such a voltage-dependent shift is common to different myotonic
mutations (Pusch, 2002); the total lack of chloride currents within the
physiological range of membrane voltages easily explains the hyper-
excitability of myotonic muscles and the severity of myotonia generally
observed in patients either homozygous for G190S or carrying G190S
together with another mutation (Modoni et al., 2011; Shalata et al.,
2010). Interestingly, three patients carrying the G190S mutation
displayed a profound transitory depression of CMAP under neurophysio-
logic examination (Modoni et al., 2011), in accord with the proposedrelationship between the shift of open probability curve and the CMAP
decrement (Colding-Jorgensen, 2005).
The dramatic reduction of current densities with A531V is in accord
with a previous study suggesting that the mutation may alter the
trafﬁcking of the channel toward the plasma membrane (Papponen
et al., 2008). Nevertheless, our patch-clamp recordings, especially
using high chloride internal solution, demonstrate that a number of
functional mutant channels reach the plasma membrane and that the
mutation does not modify channel gating. A recent study showing the
539J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540enhanced degradation of A531V conﬁrms our observation (Lee et al.,
2013). Because ion channel trafﬁcking toward themembrane is notably
dependent on a number of parameters, including temperature, calcium
ion concentration and, more generally, cell metabolism, there is a possi-
bility that membrane expression of A531V may endorse signiﬁcant
variations between individuals or physiological conditions, which
would contribute to the reported variability in clinical manifestation
and neurophysiologic transitory depression testing (Modoni et al.,
2011; Sun et al., 2001). In addition, such amechanismoffers a possibility
for developing pharmacological chaperones with therapeutic value. Such
drugs would be able to increase the membrane expression of A531V
channels, resulting in fully functional chloride currents.
The F167L mutation has been reported in various patient groups
suffering from recessive myotonia congenita (George et al., 1994;
Meyer-Kleine et al., 1995; Michel et al., 2007; Modoni et al., 2011; Ulzi
et al., 2012). A previous patch-clamp examination using high-chloride
internal concentration showed a small positive shift of Po voltage
dependence, and slight alteration of deactivation kinetics (Zhang et al.,
2000). In the current study, we found no signiﬁcant difference with
WT in chloride current density, voltage-dependence, and gating, either
in high, intermediate, or low chloride ion concentration inside.
Although F167 is not well conserved among CLC protein family
members, most of the ClC channels display an aromatic residue at this
position (tryptophan or tyrosine), except for ClC-7 that shows the
non-aromatic leucine as the mutated ClC-1 in myotonic patients
(Fig. 8). Nevertheless, F167L appears unlikely as a benign polymor-
phism in ClC-1, because it has never been found in ClC-1 of numerous
control individuals. In addition, the contemporaneous occurrence of
F167L in a DM2 patient was associated with unusual clinical ﬁndings,
suggesting a pathogenic role for the ClC-1 channel mutation (Cardani
et al., 2012).
In our previous and in the present study, F167L was found in associ-
ation with seven different mutations in patients with recessive MC
(Modoni et al., 2011). We thus studied the ﬁve exonic mutations associ-
ated with F167L, as none of these mutations have been previously
functionally characterized. Among these, the G284R, G355R, and
Y686X mutants did not generate any chloride currents in transfected
HEK cells, suggesting a defect in protein synthesis or translocation to
the membrane. Both G284 and G355 are well conserved residues
among ClC proteins, located in the putative transmembrane S8 and
S10 segments. Their substitution by a charged arginine residue
dramatically abolished chloride currents. The Y686X mutation results
in a truncated channel lacking the CBS2 domain and a major part of
the CBS1–CBS2 linker in the C-terminal intracellular tail of the channel,channel position Amino acids
CLC-1 F167 L Q F L V W V
CLC-2 Y140 L Q Y L A W V
CLC-KA Y99 L R Y L S W T
CLC-KB Y99 L R Y L S W T
CLC-4 W159 L N Y L M Y I
CLC-5 W216 V N Y F M Y V
CLC-3 W217 M N Y I M Y I
CLC-6 F135 L S L L E L L
CLC-7 L182 F S L L L W A
channel position Amino acids
CLC-1 R105 S K C Q D C I
CLC-2 R78 A R C R V C S
CLC-KA E37 R R A I Q G G
CLC-KB E37 R R G I R G G
CLC-4 K52 D R H R K I T
CLC-5 K109 D R H R E I T
CLC-3 K110 E R H R R I N
CLC-6 L62 D R C I N D P
CLC-7 L108 D N S E N Q L
Fig. 8.Multiple amino acid sequence alignmenwhich likely results in defective transport to the membrane (Estevez
et al., 2004). The lack of chloride current with these mutants conﬁrms
their pathogenicity in producing myotonia. Despite such a drastic effect,
patients carrying these mutations have a mild clinical phenotype and
show a limited CMAP depression, suggesting that F167L, which behaves
very similarly to WT, might temper the severity of symptoms. Indeed,
homozygosity for G355R can produce a severe myotonic phenotype
(Deymeer et al., 1998).
In symmetrical chloride, the P558S mutation introduced a singular
slow activation of chloride currents at negative voltages, resulting in
an increased Po at V b −100 mV. Such effect was not observed using
the low chloride internal solution. Interestingly, a similar effect has
been described for the nearby T550M mutation (Wu et al., 2002),
suggesting that alteration of the putative intramembrane P segment,
containing both T550 and P558, can profoundly affect the gating of
ClC-1 channels. Nevertheless, this speciﬁc biophysical defect develops
at very negative voltages and in high internal chloride only, and is
unlikely involved in the pathogenicity of the mutant. Conversely,
another effect of P558S consists in the drastic reduction of chloride
current densities at physiological membrane voltages, which is likely
responsible for muscle hyperexcitability. In this speciﬁc context, the
F167L mutation does not mitigate the clinical phenotype, which is
characterized by severe generalized myotonia and muscle stiffness;
whether P558S may exert a dominant negative effect on F167L would
require further investigation. Another possibility may be the expression
of disease modiﬁers in the P558S/F167L carrier.
The mutation R105C was ﬁrst identiﬁed in a German patient and
then in a patient from Southern Italy, both suffering from recessive
myotonia (Meyer-Kleine et al., 1995; Modoni et al., 2011). A charged
amino acid residue (arginine or lysine) is present at this position in 5
members of the CLC protein family but absent from 4 others (Fig. 8).
We show here that the substitution of cysteine for arginine has little
effect on ClC-1 gating. The unique effect is a small and nonsigniﬁcant
reduction of current density compared to wild-type in low internal
chloride condition. Thus the pathogenic mechanism of R105C remains
elusive as for F167L. Interestingly, the Italian patient carrying R105C
shows the most severe clinical phenotype among F167L-carrying
patients, including signiﬁcant transitory CMAP depression under neuro-
physiological test, lower limbs hypertrophy, and occasional need of the
antimyotonic drug mexiletine (200 mg a day), thereby suggesting
unrevealed pathogenic mechanisms of these mutations or the presence
of disease modiﬁers (Modoni et al., 2011).
Acetazolamide has been used empirically for its beneﬁcial action on a
variety of disorders of skeletal muscle membrane excitability includingT F P L V L I L F S A
T Y P V V L I T F S A
V Y P V A L V S F S S
V Y P V A L V S F S S
L W A L L F A F L A V
L W A L L F A F L A V
F W A L S F A F L A V
G F N L T F V F L A S
T L N A A F V L V G S
H R L G Q V V R R K L 
V R C H K F L V S R V
L E W L K Q K V F R L
L E W L K Q K L F R L 
S K S K E S I W E F I
N K S K E S T W A L I
S K K K E S A W E M T 
Y L E V L E T M D N K
F L E E E R R I N H T 
ts of human ClC proteins with Clustal 2.1.
540 J.-F. Desaphy et al. / Experimental Neurology 248 (2013) 530–540sodium and chloride channel myotonias, paramyotonia, hyper- and
hypokalemic periodic paralysis, and Andersen's syndrome (Griggs
et al., 1978; Ruff, 2006). One possible mechanism accounting for
membrane electrical stabilization by ACTZ likely consists in the opening
of calcium-activated potassium channels (Tricarico et al., 2000). More
recently, it was proposed that the drug is also able to shift ClC-1 open
probability toward more negative voltage, resulting in an increased
chloride current and consequent membrane voltage stabilization
(Eguchi et al., 2006). Because G190S induced a great positive shift of
ClC-1 open probability, we wondered whether ACTZ may be able to
counteract the effect of themutation. Althoughwewere able to conﬁrm
activating effects of ACTZ on WT channels, no signiﬁcant effect was
observed on G190S chloride currents, suggesting that the mutation
hampers channel sensitivity to the drug and possibly to intracellular pH.
In conclusion, the functional characterization of a large spectrum of
recessive ClC-1 mutations underscores a variety of molecular mecha-
nisms, all leading to a reduction of chloride currents likely responsible
for the clinical phenotype. Our study suggests that these mechanisms
may however inﬂuence the clinical phenotype. For instance, it appears
that the great shift of channel activation toward positive voltages, as
for G190S, is a likely promoter of transitory depression and weakness.
Such a knowledge is of fundamental importance for the development
of selective drugs able to correct speciﬁcally the biophysical defect and
to exert efﬁcient and safe antimyotonia therapy. Selective ligands for
ClC-1 channels are dramatically lacking, although recent progress have
been reported in identifying potent inhibitors of various ClC proteins
(Liantonio et al., 2008; Matulef et al., 2008). Although acetazolamide
increases wild-type chloride currents in vitro, ClC-1 mutations can
impair such effect and may limit its clinical efﬁciency, especially in
recessive carriers. Further studies arewarranted to complete our under-
standing of the genotype–phenotype relationship in chloride channel
myotonia and to identify promising antimyotonia therapeutics.Conﬂict of interest
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